metformin

Doran, W., Tunnicliffe, L., Muzambi, R., Rentsch, C. T., Bhaskaran, K., Smeeth, L., et al. (2024). Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. Bmj Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2023-003548

View

Pollock, C., Sanchez, J. J. G., Carrero, J. J., Kumar, S., Pecoits-Filho, R., Lam, C. S. P., et al. (2023). Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification. Diabet Med, e15200. http://doi.org/10.1111/dme.15200

View

Zheng, B., Su, B., Ahmadi-Abhari, S., Kapogiannis, D., Tzoulaki, I., Riboli, E., & Middleton, L. (2023). Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment. Alzheimers Dement. http://doi.org/10.1002/alz.13349

View